Results 41 to 50 of about 30,536 (239)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal, 2021
FLT3 mutations occur in 20 – 35% patients with newly diagnosed (ND) acute myeloid leukemia (AML) and confer a higher risk of relapse and inferior overall survival (OS).
A. Maiti, C. Dinardo, N. Daver, C. Rausch, F. Ravandi, T. Kadia, N. Pemmaraju, G. Borthakur, P. Bose, G. Issa, N. Short, M. Yilmaz, G. Montalban-Bravo, A. Ferrajoli, E. Jabbour, N. Jain, M. Ohanian, Koichi Takahashi, P. Thompson, S. Loghavi, Kathryn S. Montalbano, S. Pierce, W. Wierda, H. Kantarjian, M. Konopleva   +24 more
semanticscholar   +1 more source

Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium

American journal of hematology/oncology, 2022
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. Epigenetic changes can result in gene expression alterations which are thought to contribute to both leukemogenesis and chemotherapy resistance. We report
L. Pommert, E. Schafer, J. Malvar, N. Gossai, Ellynore Florendo, Kirthi Pulakanti, Katelyn E. Heimbruch, C. Stelloh, Yueh-Yun Chi, R. Sposto, Sridhar Rao, V. Huynh, P. Brown, B. Chang, Susan I. Colace, M. Hermiston, K. Heym, Raymond J Hutchinson, J. Kaplan, R. Mody, T. O’Brien, A. Place, Peter H Shaw, D. Ziegler, A. Wayne, D. Bhojwani, M. Burke   +26 more
semanticscholar   +1 more source

Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation

MedComm, 2023
Patients with relapsed/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine‐plus‐camrelizumab therapy, while long‐term outcome especially after treatment discontinuation remains unclear.
Chunmeng Wang, Yuting Pan, Yang Liu, Bing Guo, Jinhong Shi, Guanghua Rong, Zhipeng Guo, Zhifang Li, Qingming Yang, Jing Nie, Weidong Han   +10 more
doaj   +1 more source

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study [PDF]

, 2015
OBJECTIVE: Plasma miRNAs represent potential minimally invasive biomarkers to monitor and predict outcomes from chemotherapy. The primary goal of the current study-consisting of patients with recurrent, platinum-resistant ovarian cancer-was to ...
Benson, Eric A., Liu, Yunlong, Matei, Daniela, Nephew, Kenneth P., Skaar, Todd C.   +4 more
core   +11 more sources

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]

PLoS ONE, 2014
Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet, Dongmin Dang, Stacy Achdjian, Yi Ye, Samuel G Katz, Brian L Schmidt   +5 more
doaj   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells [PDF]

, 2016
Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens.
Bear, Harry D., Graham, Laura, Idowu, Michael O., Keim, Rebecca, Manjili, Masoud H., Payne, Kyle K., Toor, Amir A., Wan, Wen, Wang, Xiang-Yang   +8 more
core   +2 more sources

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

npj Breast Cancer, 2023
TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression.
Ming Zhao, Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans, Fei Yang, Argun Akcakanat, Marco Roberto Estecio, Debu Tripathy, Ecaterina E. Dumbrava, Senthil Damodaran, Funda Meric-Bernstam   +12 more
doaj   +1 more source

Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates [PDF]

, 2017
We present the anticancer properties of cis, cis, trans-[Pt(IV)(NH3)2Cl2(OA)2] [Pt(IV)diOA] (OA = octanoato), Pt(IV) derivative of cisplatin containing two OA units appended to the axial positions of a six-coordinate Pt(IV) center.
Brabec, Viktor, Gandin, Valentina, Gibson, Dan, Kasparkova, Jana, Marzano, Cristina, Novohradsky, Vojtech, Osella, Domenico, Pracharova, Jitka, Zanellato, Ilaria   +8 more
core   +1 more source

Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial

Journal of Clinical Oncology, 2020
PURPOSE Relapse is a major cause of treatment failure after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia (HR-AML).
Lei Gao, Yanqi Zhang, Sanbin Wang, P. Kong, Yi Su, Jiong Hu, M. Jiang, H. Bai, Tao Lang, Jishi Wang, Li Liu, Tonghua Yang, Xiao-bing Huang, Fang Liu, S. Lou, Yao Liu, Cheng Zhang, Hong Liu, Li Gao, Jia Liu, Lidan Zhu, Q. Wen, Ting Chen, Ping Wang, J. Rao, M. Mao, Cun-bang Wang, X. Duan, L. Luo, Xian-gui Peng, Kaniel Cassady, J. Zhong, Xi Zhang   +32 more
semanticscholar   +1 more source